FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310120267> ?p ?o ?g. }

• W4310120267 endingPage "6208" @default.
• W4310120267 startingPage "6206" @default.
• W4310120267 abstract "Background: Pevonedistat (PEV) is an inhibitor of NEDD8-activating enzyme (NAE) which is critical for degradation of several cellular proteins essential for tumor growth and survival. The combination of azacitidine (AZA) and venetoclax (VEN) is approved for patients (pts) with newly diagnosed (ND) AML who are unsuitable for intensive chemotherapy, and clinical studies show preliminary efficacy with AZA+VEN in higher risk MDS pts. We evaluate the efficacy and safety of the combination of AZA, VEN, and PEV in ND secondary AML (s-AML) and in MDS after HMA failure. Methods: This phase 1/2 trial enrolled pts with ND s-AML, including therapy-related AML (t-AML), AML from prior MDS or chronic myelomonocytic leukemia (CMML) or myeloproliferative neoplasm (MPN), or AML with dysplasia in ≥50% cells in ≥2 myeloid lineages (MRC). A second arm enrolled pts with MDS or CMML that had progressed on prior HMA therapy. Pts had to have a performance status ≤2, total bilirubin ≤1.5 x upper limit of normal (ULN), ALT/AST ≤2.5 x ULN, and creatinine clearance ≥30 mL/min. Pts in AML arm may have received prior HMA for preceding hematologic malignancy. In both AML and MDS/CMML cohorts, pts received AZA 75 mg/m2 SC/IV on days 1-7 and PEV 20 mg/m2 IV on days 1, 3 and 5 on every 28 day-cycle. In AML cohort, VEN was given on days 1-28 in cycle 1 and days 1-21 on cycle 2+. In MDS/CMML cohort, VEN was given on days 3-14 in cycle 1 and days 1-14 on cycle 2+. In initial phase 1 portion of the study (AML cohort only), VEN at max dose 200 mg and 400 mg were explored. Results: Between 3/2019 and 8/2021, 32 pts with AML (10 t-AML, 22 AML from MDS/CMML/MPN, 4 MRC) and 8 pts with MDS/CMML post-HMA failure (6 with MDS, 2 with CMML) were treated (Table). In the AML cohort, the median age was 74 years, with 14 pts (44%) ≥75 years of age. Cytogenetics was adverse in 21 pts (66%), and adverse risk mutations, including TP53, RUNX1, and ASXL1 were present in 34%, 31%, and 22%, respectively. 17 pts (53%) had treated secondary AML (ts-AML; i.e. prior exposure to HMA or chemotherapy for preceding myeloid neoplasm). The overall response rate (ORR, defined as CR+CRi+MLFS) was 75%, with CR in 15 pts (47%), CRi in 6 pts (19%), and MLFS in 3 pts (9%). One pt achieved PR (3%). 78% of pts achieved best response after 1 cycle of therapy (range, 1-4 cycles to best response). Among 21 pts with CR/CRi, 10 pts (48%) achieved MRD negativity by flow cytometry. 14/21 pts (67%) with poor-risk cytogenetics responded, compared to 10/11 pts (91%) with non-poor cytogenetics. 9/11 pts (82%) with TP53-mutated AML responded. 11/17 pts (65%) with ts-AML responded, compared with 13/15 pts (87%) who did not have ts-AML. With median follow up of 20 months (mos) for the AML cohort, the median OS was 8.2 mos and median relapse-free survival (RFS) was 7.4 mos. 5 pts proceeded to transplant in first remission. The median OS for pts with adverse cytogenetics was 6.8 mos and was not reached in pts without adverse cytogenetics (1-year OS of 70%). The median OS for pts with TP53-mutated AML (n=11) was 8.1 mos, pts with inv(3) (n=4) was 3.8 mos, and pts without TP53 mutation or inv(3) (n=17) was 18 mos (Figure). In MDS/CMML HMA failure cohort, the median age was 73 years. Most pts had adverse cytogenetics (50%) and were high to very high-risk by IPSS-R (87%). Overall response rate (CR+marrow CR [mCR]+HI) was 75%, with CR in 3 pts (37%), mCR in 2 pts (25%), and HI in 1 pts (13%). With a median follow up of 11 mos, the median OS was 9.9 mos. Transformation to AML occurred in 1 pt (after 11 mos). No DLTs were observed in the phase 1 portion, and VEN 400 mg daily was the recommended phase 2 dose. Myelosuppression was similar to expectations with AZA+VEN alone. Grade 3/4 non-hematologic adverse events occurring in ≥10% pts were febrile neutropenia or other infection in 75%, hypophosphatemia in 22%, and hyperbilirubinemia in 10%. The 4-week and 8-week mortality rates were 9% and 25% in AML cohort and 0% and 13% in MDS/CMML cohort, respectively. Conclusion: AZA, VEN, and PEV combination is active and well-tolerated in both ND s-AML and MDS/CMML after HMA failure. This population was enriched with very poor risk features, including a majority of pts in the AML cohort with prior HMA or chemotherapy exposure for an antecedent myeloid malignancy and 1/3 of pts with a TP53 mutation. Response rates were high across disease subgroups, although duration of responses and survival were modest in pts with historically poor risk features, including those with adverse risk cytogenetics and TP53 mutations. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310120267 created "2022-11-30" @default.
• W4310120267 creator A5001984646 @default.
• W4310120267 creator A5002348057 @default.
• W4310120267 creator A5009316700 @default.
• W4310120267 creator A5010786159 @default.
• W4310120267 creator A5015101485 @default.
• W4310120267 creator A5020626623 @default.
• W4310120267 creator A5021380291 @default.
• W4310120267 creator A5028081179 @default.
• W4310120267 creator A5028622482 @default.
• W4310120267 creator A5029750735 @default.
• W4310120267 creator A5049385583 @default.
• W4310120267 creator A5051949215 @default.
• W4310120267 creator A5053972408 @default.
• W4310120267 creator A5057106377 @default.
• W4310120267 creator A5059091760 @default.
• W4310120267 creator A5059600583 @default.
• W4310120267 creator A5060610152 @default.
• W4310120267 creator A5061026876 @default.
• W4310120267 creator A5065499641 @default.
• W4310120267 creator A5070065917 @default.
• W4310120267 creator A5070528077 @default.
• W4310120267 creator A5073446473 @default.
• W4310120267 creator A5079262854 @default.
• W4310120267 creator A5087551533 @default.
• W4310120267 creator A5091492845 @default.
• W4310120267 date "2022-11-15" @default.
• W4310120267 modified "2023-10-17" @default.
• W4310120267 title "A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure" @default.
• W4310120267 doi "https://doi.org/10.1182/blood-2022-165359" @default.
• W4310120267 hasPublicationYear "2022" @default.
• W4310120267 type Work @default.
• W4310120267 citedByCount "0" @default.
• W4310120267 crossrefType "journal-article" @default.
• W4310120267 hasAuthorship W4310120267A5001984646 @default.
• W4310120267 hasAuthorship W4310120267A5002348057 @default.
• W4310120267 hasAuthorship W4310120267A5009316700 @default.
• W4310120267 hasAuthorship W4310120267A5010786159 @default.
• W4310120267 hasAuthorship W4310120267A5015101485 @default.
• W4310120267 hasAuthorship W4310120267A5020626623 @default.
• W4310120267 hasAuthorship W4310120267A5021380291 @default.
• W4310120267 hasAuthorship W4310120267A5028081179 @default.
• W4310120267 hasAuthorship W4310120267A5028622482 @default.
• W4310120267 hasAuthorship W4310120267A5029750735 @default.
• W4310120267 hasAuthorship W4310120267A5049385583 @default.
• W4310120267 hasAuthorship W4310120267A5051949215 @default.
• W4310120267 hasAuthorship W4310120267A5053972408 @default.
• W4310120267 hasAuthorship W4310120267A5057106377 @default.
• W4310120267 hasAuthorship W4310120267A5059091760 @default.
• W4310120267 hasAuthorship W4310120267A5059600583 @default.
• W4310120267 hasAuthorship W4310120267A5060610152 @default.
• W4310120267 hasAuthorship W4310120267A5061026876 @default.
• W4310120267 hasAuthorship W4310120267A5065499641 @default.
• W4310120267 hasAuthorship W4310120267A5070065917 @default.
• W4310120267 hasAuthorship W4310120267A5070528077 @default.
• W4310120267 hasAuthorship W4310120267A5073446473 @default.
• W4310120267 hasAuthorship W4310120267A5079262854 @default.
• W4310120267 hasAuthorship W4310120267A5087551533 @default.
• W4310120267 hasAuthorship W4310120267A5091492845 @default.
• W4310120267 hasConcept C104317684 @default.
• W4310120267 hasConcept C126322002 @default.
• W4310120267 hasConcept C143998085 @default.
• W4310120267 hasConcept C150194340 @default.
• W4310120267 hasConcept C185592680 @default.
• W4310120267 hasConcept C190727270 @default.
• W4310120267 hasConcept C2776012956 @default.
• W4310120267 hasConcept C2776063141 @default.
• W4310120267 hasConcept C2776239401 @default.
• W4310120267 hasConcept C2776364478 @default.
• W4310120267 hasConcept C2777928532 @default.
• W4310120267 hasConcept C2777938653 @default.
• W4310120267 hasConcept C2778461978 @default.
• W4310120267 hasConcept C2778729363 @default.
• W4310120267 hasConcept C2779282312 @default.
• W4310120267 hasConcept C2779675984 @default.
• W4310120267 hasConcept C2780007613 @default.
• W4310120267 hasConcept C2780235182 @default.
• W4310120267 hasConcept C2780817109 @default.
• W4310120267 hasConcept C55493867 @default.
• W4310120267 hasConcept C71924100 @default.
• W4310120267 hasConcept C90924648 @default.
• W4310120267 hasConceptScore W4310120267C104317684 @default.
• W4310120267 hasConceptScore W4310120267C126322002 @default.
• W4310120267 hasConceptScore W4310120267C143998085 @default.
• W4310120267 hasConceptScore W4310120267C150194340 @default.
• W4310120267 hasConceptScore W4310120267C185592680 @default.
• W4310120267 hasConceptScore W4310120267C190727270 @default.
• W4310120267 hasConceptScore W4310120267C2776012956 @default.
• W4310120267 hasConceptScore W4310120267C2776063141 @default.
• W4310120267 hasConceptScore W4310120267C2776239401 @default.
• W4310120267 hasConceptScore W4310120267C2776364478 @default.
• W4310120267 hasConceptScore W4310120267C2777928532 @default.
• W4310120267 hasConceptScore W4310120267C2777938653 @default.
• W4310120267 hasConceptScore W4310120267C2778461978 @default.
• W4310120267 hasConceptScore W4310120267C2778729363 @default.
• W4310120267 hasConceptScore W4310120267C2779282312 @default.
• W4310120267 hasConceptScore W4310120267C2779675984 @default.

• next